Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment‐resistant schizophrenia, even in 22qDS.
Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness / Accinni, Tommaso; Frascarelli, Marianna; Ghezzi, Francesco; Panzera, Alessia; Buzzanca, Antonino; Fanella, Martina; Di Bonaventura, Carlo; Carlone, Luca; Girardi, Nicoletta; Pasquini, Massimo; Di Fabio, Fabio. - In: CLINICAL CASE REPORTS: OPEN ACCESS. - ISSN 2582-5038. - (2021). [10.1002/ccr3.4134]
Titolo: | Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness | |
Autori: | DI FABIO, FABIO (Ultimo) [Supervision] | |
Data di pubblicazione: | 2021 | |
Rivista: | ||
Citazione: | Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness / Accinni, Tommaso; Frascarelli, Marianna; Ghezzi, Francesco; Panzera, Alessia; Buzzanca, Antonino; Fanella, Martina; Di Bonaventura, Carlo; Carlone, Luca; Girardi, Nicoletta; Pasquini, Massimo; Di Fabio, Fabio. - In: CLINICAL CASE REPORTS: OPEN ACCESS. - ISSN 2582-5038. - (2021). [10.1002/ccr3.4134] | |
Handle: | http://hdl.handle.net/11573/1615695 | |
Appartiene alla tipologia: | 01i Case report |
File allegati a questo prodotto
File | Note | Tipologia | Licenza | |
---|---|---|---|---|
Accinni_Clozapine-induced gastroesophageal rumination_2021.pdf | Versione editoriale (versione pubblicata con il layout dell'editore) | ![]() | Open Access Visualizza/Apri |